SCHEMBL1678581

SCHEMBL1678581

COc1cc(Cl)ccc1CC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.54
CHRM1 P11229 1/20 0.54
GAA P10253 5/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
LMNA P02545 2/20 0.50
KDM4C Q9H3R0 1/20 0.49
NR1H4 Q96RI1 1/20 0.49
FFAR4 Q5NUL3 1/20 0.48
KDM4E B2RXH2 1/20 0.48
ACLY P53396 1/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CAMK2A Q9UQM7 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29531142 1.00 HSD17B10 (0.54) HSD17B10CHRM1GAAMEN1KMT2A
SCHEMBL29531114 0.86 MEN1 (0.47) GAAMEN1KMT2ALMNAKDM4C
SCHEMBL10863796 0.86 CYP3A4 (0.61) GAAMEN1KMT2ALMNAKDM4C
SCHEMBL3870178 0.86 HSD17B10 (0.68) HSD17B10CHRM1GAAMEN1KMT2A
SCHEMBL6482114 0.86 MEN1 (0.47) GAAMEN1KMT2ALMNAKDM4C
SCHEMBL19428172 0.85 LMNA (0.49) GAAMEN1KMT2ALMNAKDM4C
SCHEMBL30154489 0.85 MEN1 (0.50) GAAMEN1KMT2ALMNAKDM4C
SCHEMBL19411026 0.85 MEN1 (0.50) GAAMEN1KMT2ALMNAKDM4C
SCHEMBL21900449 0.83 CHRM1 (0.51) CHRM1GAAMEN1KMT2AKDM4C
SCHEMBL4090952 0.82 CHRM1 (0.73) HSD17B10CHRM1GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363403-B1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(1H-INDOL-3-YL)ETHENONE DERIVATIVES UNIV LEUVEN KATH (BE) 2026-05-27 EP claimed
US-20240308959-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-09-19 US claimed
CN-117616010-A Process for preparing (S) -2- (4-chloro-2-methoxyphenyl) -2- ((3-methoxy-5- (methylsulfonyl) phenyl) amino) -1- (1H-indol-3-yl) ketene derivatives 杨森制药公司 2024-02-27 CN claimed
EP-3896072-B1 MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS JANSSEN PHARMACEUTICALS INC (US) 2022-11-16 EP claimed
US-20260144743-A1 COMPOUNDS TMEM16A LIMITED (GB) 2026-05-28 US disclosed
EP-4363403-B1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL)PHENYL)AMINO)-1-(1H-INDOL-3-YL)ETHENONE DERIVATIVES UNIV LEUVEN KATH (BE) 2026-05-27 EP disclosed
EP-4240331-B1 SOLID FORMULATION UNIV LEUVEN KATH (BE) 2026-04-29 EP disclosed
EP-4720034-A1 NOVEL COMPOUNDS TO TREAT VIRAL INFECTIONS Zydus Lifesciences Limited (IN) 2026-04-08 EP disclosed
EP-4699655-A2 COMPOUNDS TMEM16A LIMITED (GB) 2026-02-25 EP disclosed
EP-4680336-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2026-01-21 EP disclosed
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2026-01-08 US disclosed
US-12377105-B2 Compounds TMEM16A LIMITED (GB) 2025-08-05 US disclosed
EP-1806332-A1 BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS Daiichi Sankyo Company, Limited (JP) 2007-07-11 EP disclosed
EP-1765768-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES AstraZeneca AB (SE) 2007-03-28 EP disclosed
WO-2006005909-A1 SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES ASTRAZENECA AB (SE) 2006-01-19 WO disclosed
US-6939888-B2 1-H-3-arylpirrolidine-2,4-dione derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-09-06 US disclosed
US-20040019061-A1 1-H-3-arylpirrolidine-2,4-dione derivatives FISCHER REINER (DE) 2004-01-29 US disclosed
US-6472419-B1 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents BAYER AKTIENGESELLSCHAFT (DE) 2002-10-29 US disclosed
EP-0741700-A1 1-H-3-ARYLPYRROLIDINE-2,4-DIONE DERIVATIVES AS PEST-CONTROL AGENTS BAYER AG (DE) 1996-11-13 EP disclosed
WO-1995020572-A1 1-H-3-ARYLPYRROLIDINE-2,4-DIONE DERIVATIVES AS PEST-CONTROL AGENTS BAYER AKTIENGESELLSCHAFT (DE) 1995-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144743-A1 COMPOUNDS CACNA1E, TMEM109, CACNA1C HSD17B10 868/4885CHRM1 493/4885GAA 1568/4885
US-20040019061-A1 1-H-3-arylpirrolidine-2,4-dione derivatives PRXL2A, DDT, CYP4B1 HSD17B10 1742/4885CHRM1 311/4885GAA 1674/4885
US-20240308959-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES HTR3C, CCND3, H1-3 HSD17B10 925/4885CHRM1 77/4885GAA 4807/4885
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NOD1, NLRP3, NOD2 HSD17B10 984/4885CHRM1 1445/4885GAA 1855/4885
US-12377105-B2 Compounds CACNA1E, TMEM109, CACNA1A HSD17B10 2273/4885CHRM1 158/4885GAA 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.